GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
17 Dezembro 2024 - 11:00AM
Business Wire
50 Million Americans Face Critical Gaps in Care
as Demand for Endocrinologists Surges
Living in an Endocrinology Desert Increases
Mortality Risk by 12%, Study Finds
GoodRx (Nasdaq: GDRX), the leading prescription savings platform
in the U.S., today revealed startling healthcare disparities in its
new report, “Endocrinologist Deserts: A Critical Healthcare Gap for
Millions in the U.S.” With nearly 70% of U.S. counties lacking an
endocrinologist, the report paints a stark picture of the barriers
millions of Americans face in managing life-threatening conditions
like diabetes.
The findings come at a critical time as the prevalence of
diabetes continues to surge nationwide. Over 38 million Americans
are living with diabetes, yet many cannot access the specialized
care needed to manage their condition effectively. Endocrinologists
play a critical role in diagnosing and managing complex hormonal
and metabolic conditions, including diabetes, obesity, menopause,
thyroid disorders, and more. But for 50 million Americans in
endocrinology deserts, help is likely out of reach. The lack of
access correlates with significantly higher rates of diabetes
complications, obesity, stroke, and even death.
Key findings from the report include:
- Nearly 70% of U.S. counties are entirely without an
endocrinologist, leaving millions to delay treatment, travel
long distances, or go without care altogether.
- People in counties without endocrinologists face a 12%
higher mortality rate from endocrine-related diseases, along
with elevated rates of diabetes complications, obesity, and stroke.
For patients, this could mean more hospital visits, increased
medical expenses, and worse health outcomes.
- Diabetes death rates soar in endocrinology deserts, more
than doubling in places like Buffalo County, South Dakota (143.3
per 100,000), compared to Bell County, Kentucky (56.6 per 100,000)
where specialists are available.
“The shortage of endocrinologists creates a critical barrier to
care, leaving millions unable to manage life-altering conditions—a
challenge compounded by rising medication costs and pharmacy
closures,” said Tori Marsh, MPH, Director of Research at GoodRx.
“Addressing these disparities requires innovative, equitable
solutions like telemedicine and incentives for specialists to serve
underserved areas, ensuring all patients have access to the
treatment they need.”
GoodRx is dedicated to supporting people with diabetes by making
essential care more accessible through substantial savings on
medications and devices like continuous glucose monitors, as well
as expert-created health content to empower individuals to make
informed health decisions for themselves and their families. Key
offerings include:
- Savings on generic diabetes medications. Save up to 80%
off diabetes medications, with 20 medications under $20 to treat
diabetes and related conditions.
- Exclusive brand-name discounts. Save on commonly
prescribed GLP-1 and GIP medications.
- Trusted health resources. Visit the Diabetes Center for
expert advice and treatment options written by doctors,
pharmacists, and health experts.
The full endocrinology desert report is available from GoodRx
Research, here.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding anticipated consumer savings and
accessibility; and the objectives and potential benefits and value
of the GoodRx research and savings. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause GoodRx’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, risks relating to GoodRx’s ability to achieve
broad market education and change consumer purchasing habits,
changes in medication pricing and pricing structures, GoodRx’s
reliance on a limited number of industry participants, and the
important factors discussed in the section entitled “Risk Factors”
in GoodRx’s Annual Report on Form 10-K for the year ended December
31, 2023, and GoodRx’s other filings with the Securities and
Exchange Commission. Any such forward-looking statements are based
on current expectations, projections and estimates as of the date
of this press release. While GoodRx may elect to update such
forward-looking statements at some point in the future, GoodRx
disclaims any obligation to do so, even if subsequent events cause
GoodRx’s views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241217013913/en/
Media Contact press@goodrx.com
GoodRx (NASDAQ:GDRX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
GoodRx (NASDAQ:GDRX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
